Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Immunity

• Publication date

  1997-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1074-7613(00)80397-0PMID 9430224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MHC ligands and peptide motifs: first listing

  2004cited by this paper
• Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids

  2004cited by this paper
• MHC Ligands and Peptide Motifs

  1998cited by this paper
• A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter.

  1997cited by this paper
• Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

  1997cited by this paper
• The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP.

  1997cited by this paper
• Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.

  1997cited by this paper
• Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response

  1997cited by this paper
• Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.

  1997cited by this paper
• Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.

  1997cited by this paper
• The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol.

  1996cited by this paper
• Human cytomegalovirus inhibits antigen presentation by a sequential multistep process.

  1996cited by this paper
• Epitope focusing in the primary cytotoxic T cell response to Epstein- Barr virus and its relationship to T cell memory

  1996cited by this paper
• Antigen processing and presentation by the class I major histocompatibility complex.

  1996cited by this paper
• Cytomegalovirus selectively blocks antigen processing and presentation of its immediate–early gene product

  1996cited by this paper
• Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines.

  1996cited by this paper
• Sec6l-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction

  1996cited by this paper
• A new foreign policy: MHC class I molecules monitor the outside world.

  1996cited by this paper
• Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains.

  1996cited by this paper
• Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages.

  1995cited by this paper
• Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1

  1995cited by this paper
• A viral inhibitor of peptide transporters for antigen presentation

  1995cited by this paper
• Herpes simplex virus turns off the TAP to evade host immunity

  1995cited by this paper
• The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis.

  1995cited by this paper
• Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I‐restricted epitope presentation

  1995cited by this paper
• Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.

  1995cited by this paper
• Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses to Epstein-Barr virus in children.

  1995cited by this paper
• Epstein‐Barr virus isolates with the major HLA B35.01‐restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01‐positive African population

  1995cited by this paper
• A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1

  1995cited by this paper
• Heat-inactivated Sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo.

  1995cited by this paper
• Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state

  1994cited by this paper
• Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease.

  1994cited by this paper
• Presentation of an exogenous antigen by major histocompatibility complex class I molecules

  1994cited by this paper
• The role of the conserved residue in pocket A and the polymorphic residue in pocket E of HLA-B*3501 in presentation of human minor histocompatibility peptides to T cells.

  1994cited by this paper
• Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4

  1993cited by this paper
• Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.

  1993cited by this paper
• Phagocytic processing of bacterial antigens for class I MHC presentation to T cells

  1993cited by this paper
• Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication

  1993cited by this paper
• Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing.

  1992cited by this paper
• Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

  1992cited by this paper
• Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens

  1992cited by this paper
• Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector.

  1992cited by this paper
• The specificity of recognition of a cytotoxic T lymphocyte epitope

  1992cited by this paper
• Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

  1992cited by this paper
• Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

  1992cited by this paper
• Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

  1991cited by this paper
• A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5.

  1988cited by this paper
• Hybrid pUC vectors for addition of new restriction enzyme sites to the ends of DNA fragments.

  1987cited by this paper
• High-frequency homologous recombination in vaccinia virus DNA

  1987cited by this paper
• Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection.

  1987cited by this paper
• DNA sequence and expression of the B95-8 Epstein—Barr virus genome

  1984cited by this paper
• One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain.

  1983cited by this paper

• Latent, Lytic, and Linked to Multiple Sclerosis—How EBV Drives Autoimmunity

  2026cites this paper
• Immune Evasion by Epstein-Barr Virus.

  2025cites this paper
• Leveraging mRNA technology for antigen based immuno-oncology therapies

  2025cites this paper
• The Epstein-Barr virus EBNA1 protein binds to G-quadruplexes in its own mRNA hence controlling its expression and immune evasion of the virus

  2025cites this paper
• Viral manipulation of the HLA class I antigen processing and presentation pathway

  2025cites this paper
• EBNA1.

  2025cites this paper
• Altered EBV specific immune control in multiple sclerosis.

  2024cites this paper
• How Epstein Barr Virus Causes Lymphomas.

  2024cites this paper
• Cross-presentation by the others.

  2023cites this paper
• Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice

  2023cites this paper
• The hide-and-seek game of the oncogenic epstein-barr virus-encoded EBNA1 protein with the immune system: An RNA G-quadruplex tale.

  2023cites this paper
• Impact of Epstein Barr Virus Infection on Treatment Opportunities in Patients with Nasopharyngeal Cancer

  2023cites this paper
• E3 Ubiquitin Ligases in Gammaherpesviruses and HIV: A Review of Virus Adaptation and Exploitation

  2023cites this paper
• Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival

  2023cites this paper
• The impact of HLA polymorphism on herpesvirus infection and disease

  2023cites this paper
• Characterization of an immune-evading doxycycline-inducible lentiviral vector for gene therapy in the spinal cord.

  2022cites this paper
• Urgency and necessity of Epstein-Barr virus prophylactic vaccines

  2022cites this paper
• Type I arginine methyltransferases are intervention points to unveil the oncogenic Epstein-Barr virus to the immune system

  2022cites this paper
• The Role of Codon Usage, tRNA Availability, and Cell Proliferation in EBV Latency and (Re)Activation

  2022cites this paper
• Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host

  2022cites this paper
• Human herpesvirus diversity is altered in HLA class I binding peptides

  2022cites this paper
• Burkitt lymphoma with a granulomatous reaction: an M1/Th1‐polarised microenvironment is associated with controlled growth and spontaneous regression

  2021cites this paper
• The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development

  2021cites this paper
• Burkitt lymphoma with a granulomatous reaction: an M1/ Th1-polarised microenvironment is associated with controlled growth and spontaneous regression lymphoma with a granulomatous reaction: an M1/Th1-polarised microenvironment is associated with controlled growth and spontaneous regression

  2021cites this paper
• The role of Epstein–Barr virus-encoded latent membrane proteins in host immune escape

  2021cites this paper
• BURKITT LYMPHOMA WITH GRANULOMATOUS REACTION: A M1/TH1-POLARIZED MICROENVIRONMENT ASSOCIATES WITH CONTROLLED GROWTH AND SPONTANEOUS REGRESSION

  2021cites this paper
• EBV Infection and Human Primary Immune Deficiencies

  2020influential citation
• Studies on prerequisites for antigen-specific active immunotherapy

  2020cites this paper
• Redirecting T Cells against Epstein–Barr Virus Infection and Associated Oncogenesis

  2020cites this paper
• HIV/AIDS-Associated Viral Oncogenesis

  2019influential citation
• The T-cell Response to Epstein-Barr Virus–New Tricks From an Old Dog

  2019cites this paper
• Heterologous prime-boost vaccination protects from EBV antigen expressing lymphomas.

  2019cites this paper
• University of Birmingham Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas

  2019cites this paper
• The Critical Role of Genome Maintenance Proteins in Immune Evasion During Gammaherpesvirus Latency

  2019cites this paper
• EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers

  2018cites this paper
• The Microenvironment in Epstein–Barr Virus-Associated Malignancies

  2018cites this paper
• EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers

  2018cites this paper
• Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.

  2018cites this paper
• Lack of Association Between Epstein–Barr Virus and Mammary Tumours in Dogs

  2018cites this paper
• Molecular Biology of EBV in Relationship to HIV/AIDS-Associated Oncogenesis.

  2018cites this paper
• Epstein Barr Virus genome variation and functional analysis of the IR-1 internal repeat

  2018influential citation
• Strategies for immune evasion by human tumor viruses.

  2018cites this paper
• Identification of immediate early gene products of bovine herpes virus 1 (BHV-1) as dominant antigens recognized by CD8 T cells in immune cattle.

  2017cites this paper
• This information is current as Carcinoma and Lymphoma Patients with EBV-Positive Nasopharyngeal Protein 2 Specificity in CTL Lines from Characterization of Latent Membrane

  2017cites this paper
• Macavirus latency-associated protein evades immune detection through regulation of protein synthesis in cis depending upon its glycin/glutamate-rich domain

  2017cites this paper
• Evaluation of novel anti-tumoral strategies using peptide or monoclonal antibody immunotherapies

  2016cites this paper
• Post-transplant lymphoproliferative disorders

  2016cites this paper
• Therapeutic vaccination strategies to treat nasopharyngeal carcinoma.

  2016cites this paper
• ii Elucidating the role of ARKL 1 in regulating Epstein-Barr virus ( EBV ) infection

  2016cites this paper
• Immunotherapy for nasopharyngeal cancer-a review.

  2016cites this paper
• Autophagy and proteasome interconnect to coordinate cross‐presentation through MHC class I pathway in B cells

  2016cites this paper
• The Use of Rabbit Model for the Efficacy of a Novel Epstein-Barr virus (EBV) Peptide Vaccine

  2016cites this paper
• Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients

  2015cites this paper
• Epstein–Barr virus‐encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV‐carrying cancers

  2015cites this paper
• Epstein Barr Virus Volume 2

  2015cites this paper
• Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells

  2015cites this paper
• The immunology of Epstein-Barr virus-induced disease.

  2015cites this paper
• Immune Evasion by Epstein-Barr Virus.

  2015cites this paper
• High Levels of IL-10 and CD4+CD25hi+ Treg Cells in Endemic Burkitt’s Lymphoma Patients

  2015cites this paper
• Effects on Protein Processing Evasion through Central Repeat Domain Mimics Epstein-Barr Virus EBNA1 Immune Latency-Associated Nuclear Antigen 1 Kaposi's Sarcoma-Associated Herpesvirus

  2014cites this paper
• Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve

  2014cites this paper
• Investigation of Epstein-Barr Virus-Host Interactions during Latent and Lytic Infection

  2014cites this paper
• EBV immune evasion genes modulating CD8+ T cell recognition during lytic cycle replication

  2014cites this paper
• G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation.

  2014cites this paper
• A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus

  2014cites this paper
• Therapeutic Vaccination against the Rhesus Lymphocryptovirus EBNA-1 Homologue, rhEBNA-1, Elicits T Cell Responses to Novel Epitopes in Rhesus Macaques

  2013cites this paper
• Nasopharyngeal Carcinoma Immunotherapy: Current Strategies and Perspectives

  2013cites this paper
• MHC II tetramers visualize human CD4+ T cell responses to Epstein–Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response

  2013cites this paper
• Pathogenesis of Endemic Burkitt's Lymphoma: The Role of T-Cell Responses

  2013cites this paper
• Individual MHCI-Restricted T-Cell Receptors are Characterized by a Unique Peptide Recognition Signature

  2013cites this paper
• The biological basis and clinical correlates of the association between EBV-positive Hodgkin lymphoma and HLA class I

  2013cites this paper
• antigen efficiently reactivate specific cytotoxic T cells Epstein-Barr virus encoding a foreign - B cells immortalized by a mini

  2013cites this paper
• virus-derived autologous lymphoblastoid cell lines Repertoire and frequency of immune cells reactive to Epstein-Barr

  2013cites this paper
• Epstein-Barr Virus (EBV) and the Effectiveness of Suberoylanilide Hydroxamic Acid (SAHA) as a Treatment for EBV Infection and Associated Cancers

  2013cites this paper
• Epstein Barr virus nuclear antigen 1 in healthy virus carriers Distinct memory CD4+ T-cell subsets mediate immune recognition of

  2013cites this paper
• Prospective analysis of the primary immune response during naturally acquired Epstein-Barr virus infection in humans

  2013cites this paper
• derived autologous lymphoblastoid cell lines - Repertoire and frequency of immune cells reactive to Epstein-Barr virus

  2013cites this paper
• dendritic cells repertoire diversity following in vitro restimulation by antigen-pulsed specific CD8+ T-cell - Characterization of human cytomegalovirus peptide

  2013cites this paper
• Nuclear Antigen 1 Gly-Ala Repeat of Epstein-Barr Virus mRNA Translation Regulation by the

  2012cites this paper
• Contributions of Epstein-Barr Nuclear Antigen 1 (EBNA1) and the Family of Repeats (FR) Region to oriP-mediated Replication and Segregation Functions in Nasopharyngeal Carcinoma

  2012cites this paper
• The Epstein-Barr Virus EBNA1 Protein

  2012cites this paper
• The role of mRNA translation in direct MHC class I antigen presentation.

  2012influential citation
• Contributions of Epstein-Barr Nuclear Antigen 1 (EBNA1) to Epithelial Cell Infections

  2012cites this paper
• Cellular Immunogenicity of Novel Gene Immunogens in Mice Monitored by in Vivo Imaging

  2012cites this paper
• Proteasome inhibitors induce the presentation of an Epstein–Barr virus nuclear antigen 1‐derived cytotoxic T lymphocyte epitope in Burkitt’s lymphoma cells

  2011cites this paper
• Expression of Epstein-Barr Virus Gene and Clonality of Infiltrated T Lymphocytes in Epstein-Barr Virus-associated Gastric Carcinoma

  2011cites this paper
• University of Birmingham Epstein-Barr Virus Evades CD4 T Cell Responses in Lytic Cycle through BZLF1-mediated Downregulation of CD74 and the Cooperation of vBcl-2.

  2011cites this paper
• Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

  2011cites this paper
• Evaluation of Epstein-Barr Virus Latent Membrane Protein 2 Specific T-Cell Receptors Driven by T-Cell Specific Promoters Using Lentiviral Vector

  2011cites this paper
• Epstein-Barr Virus Evades CD4+ T Cell Responses in Lytic Cycle through BZLF1-mediated Downregulation of CD74 and the Cooperation of vBcl-2

  2011cites this paper
• Lymphoma EBV-Positive Nasopharyngeal Carcinoma and Specificity in CTL Lines from Patients with Characterization of Latent Membrane Protein 2

  2011cites this paper
• Lymphomas differ in their dependence on Epstein-Barr virus.

  2011cites this paper
• Functional modulation of the metastatic suppressor Nm23‐H1 by oncogenic viruses

  2011cites this paper
• Strategies for vaccination against Epstein–Barr virus-associated diseases

  2010cites this paper
• Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors

  2010cites this paper
• Epstein Barr Virus-Encoded EBNA1 Interference with MHC Class I Antigen Presentation Reveals a Close Correlation between mRNA Translation Initiation and Antigen Presentation

  2010cites this paper
• Insights into the evolution of lymphomas induced by Epstein-Barr virus.

  2010cites this paper
• Folding of Matrix Metalloproteinase-2 Prevents Endogenous Generation of MHC Class-I Restricted Epitope

  2010cites this paper
• Allelic polymorphism in the T cell receptor and its impact on immune responses

  2010cites this paper
• A potentially immunologically inert derivative of the reverse tetracycline-controlled transactivator

  2010cites this paper